QuiremSpheres® is based on Holmium-166 microspheres, which were developed in the clinic as an alternative to Yttrium-90 microspheres for treating unresectable liver tumors with selective internal radiation therapy (SIRT). Holmium-166 microspheres can be imaged with SPECT and MR, with high sensitivity and resolution, respectively. This makes it possible to perform post-treatment quantitative verification of the achieved dose distribution, i.e. determining dose-to-tumor and dose-to-tissue. With QuiremSpheres® you treat what you see and see what you treat.
Q-Suite™ allows you to perform accurate post-treatment dosimetry of Holmium-166 SIRT. With Q-Suite™, you can evaluate dose absorption at a voxel level based on SPECT/CT or MR imaging and generate a comprehensive dosimetry report per patient.
QuiremSpheres® is supplied as a standard dose in a single capped V-vial or as a standard dose divided among several capped V-vials.
QuiremSpheres® is a product manufactured by Quirem Medical B.V. and has CE-mark.
QuiremSpheres® is not available for sale in all countries. This information is provided only in respect to markets where the product is approved or cleared. QuiremSpheres® is not FDA cleared in the US for sale.
QuiremSpheres® is not approved in Canada
Our sales representatives are here for you
Radifocus® Guidewire M Non-Vascular
Radifocus® Introducer II Radiopaque Marker Kit C
Radifocus® Guidewire M Shapeable Type
Didn't find your product?
This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public
This is HCP only content